MarketsandMarkets forecasts the sector will grow from $311.2 billion in 2026 at a 7.5% CAGR, with monoclonal antibodies, hospitals and specialty care centers, and North America holding the largest shares.
The global antibody therapeutics market is projected to rise to USD 597.1 billion by 2035 from USD 311.2 billion in 2026, according to MarketsandMarkets, which forecasts a 7.5% compound annual growth rate over the period. The report says demand is being driven by rising use of antibody-based drugs to treat cancer, autoimmune, inflammatory, ophthalmic, and rare diseases, alongside continued advances in next-generation formats including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. It says monoclonal antibodies remained the dominant format in 2025 with an approximately 85% share, while hospitals and specialty care centers accounted for about 78% of the market and North America held roughly 35%. MarketsandMarkets says growth is being supported by progress in antibody engineering, target discovery, conjugation chemistry, biomarker-led patient selection, and an expanding late-stage pipeline, with investment in bispecific antibodies and ADCs adding momentum.